Tailored Expertise Sourcing & Market Intelligence in Global Consulting

is a pioneer in the Extracellular Vesicle (EV) space. They have already been developing exosome-based drug candidates for the treatment and prevention of COVID-19, Long COVID, Chronic Obstructive Pulmonary Disease (COPD), osteoarthritis, and other conditions. Its flagship product, Zofin™, is in human clinical trials. Since being FDA approved for an expanded access trial, the company has also treated 18 people with the exosome-based therapy and the results are promising with patients showing reduced inflammation and improved lung function.

Extracellular vesicles (EVs) can facilitate essential communication among cells in a range of pathophysiological conditions including cancer metastasis and progression, immune regulation, and neuronal communication.

What are exosomes? For many years, exosomes were considered to be transporters of cellular waste, but they are now recognized for their essential role in intercellular communication and transportation.

Currently, there are at least 45 market competitors which compose the exosome industry in therapeutics and diagnostics. Twenty six of them are companies specializing in exosomes and nineteen of them are established companies that have recently jumped into the exosome industry.

Aging is associated with an alteration of intercellular communication. These changes in the extracellular environment contribute to the aging phenotype and have been linked to different aging-related diseases. Extracellular vesicles (EVs) are factors that mediate the transmission of signaling molecules between cells. In the aging field, these EVs have been shown to regulate important aging processes, such as oxidative stress or senescence, both in vivo and in vitro. EVs from healthy cells, particularly those coming from stem cells (SCs), have been described as potential effectors of the regenerative potential of SCs.

To better define the biological machinery associated with BK virus (BKV) infection, in kidney transplantation, we performed a proteomics analysis of urinary extracellular vesicles (EVs).

We will present the EV isolation process from clarified conditioned media and fractionation using CIMmultus™ chromatography columns. Testing of the raw materials, analysis of upstream samples produced in different cell lines, and analysis of downstream samples were performed using PATfix™ HPLC analytical approaches. The composition of EV populations was monitored through the detection of tetraspanins using immunofluorescent labelling and SEC analytics. High-throughput analysis of in-process samples and impurity composition was monitored using CIMac™ anion exchange columns.

Identifying differences between healthy and patient groups is a critical step towards biomarker development. However, there is a large gap between initial biomarker discovery studies and using an EV-based biomarker test to make clinical decisions about an individual. Early on, the goal is to identify differences between healthy and diseased groups, or between groups at different stages of disease progression – and studies are often retrospective. In the clinic, however, results are used to make decisions that affect an individual’s health outcome, and therefore have a heavier weighting. Measured parameters used to make clinical decisions must be reliable enough to establish and recognise healthy reference ranges, and/or detect changes in an individual over time.

Melanoma exosomes are crucial participants in supporting melanoma growth, metastasis, and treatment resistance. Exosome-derived componentsare vital orchestrators in the cellular crosstalk in melanoma. Melanoma-derived exosomes influence tumor progression by affecting immune cell function. Blocking vicious exosomeal components is a potential strategy for combating melanoma.

These small membrane vesicles do much more than clean up a cell’s trash—they also carry signals to distant parts of the body, where they can impact multiple dimensions of cellular life.

Small extracellular vesicles (sEVs) are membrane vesicles released by healthy and malignant cells. sEVs are potential biomarkers for cancer diagnosis. Cervical cancer (CC) is the fourth most common cancer in females worldwide. Existing biomarkers, such as squamous cell carcinoma antigens, show low specificity. Hence, a novel biomarker for the diagnosis of CC is required. This study aimed to identify potential candidates in sEVs through proteomic analysis for the diagnosis of CC and to determine the EV protein profile to distinguish between healthy and CC serum samples.

The project is examining new ways to ramp up the quantity of extracellular vesicles (EVs), produced from mesenchymal stem cells that can be manufactured in a lab to meet the therapeutic critical need for biological products. The cells have the ability to use EVs to communicate with other cells by transferring proteins, lipids and nucleic acids using EVs as a compartment. EVs produced by mesenchymal stem cells can inhibit inflammation, modulate immune responses, reduce cell die-off, and enhance tissue repair and regeneration.

Researchers have learned that the spectrum of EV subtypes is broader than initially recognized, and they are still grappling with how best to purify, analyze or even classify these diverse nano- and microparticles. Untangling their function has proven just as thorny, drawing on observations and inferences from a host of different in vitro and in vivo models with a variety of different imaging and analytical instruments. The good news is that the field is aggressively pushing for greater rigor and reproducibility, even as it arms itself with more powerful and reliable tools for untangling the enigmas of EV biology.

To date, there are numerous protocols for the isolation of extracellular vesicles (EVs). Depending on the isolation method, it is possible to obtain vesicles with different characteristics, enriched with specific groups of proteins, DNA and RNA, which affect similar types of cells in the opposite way. Therefore, it is important to study and compare methods of vesicle isolation. Moreover, the differences between the EVs derived from tumor and mesenchymal stem cells are still poorly understood.

Extracellular vesicles are emerging as important information shuttles that can coordinate and disseminate homeostatic and disease signals. These extracellular vesicles, which are present in biological fluids such as sputum, mucus, epithelial lining fluid, edema fluid, blood, pleural fluid, and lymph, have emerged as promising candidate biomarkers with diagnostic and prognostic value in lung disease. Extracellular vesicles are small subcellular membranous vesicles containing cargo from parent cells, where cargo may take the form of lipids, proteins, genetic information, or entire organelles. The cargo thus endows extracellular vesicles with biologically active information (or function) by which the extracellular vesicles can reprogram target cells. Several recent studies have documented that extracellular vesicles found in lung-associated biological fluids play key roles as biomarkers and effectors of disease.

Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

The market for stem cell exosomes is a fast-growth, high potential market. Currently in its early-stages, the market is readily posed for expansion. With a limited number of market competitors and few products in clinical-stage trials, the market is ripe for disruption by new competitors and new technologies.

EVs have powerful therapeutic effects from both naïve and loaded formats with varying payloads and influence cell behaviors. When delivered to the site itself such as in medical conditions of osteoarthritis, they can potentially be used as complementary and alternative medical therapy. EVs aid to alleviate pain or wound healing to accelerate healing. When delivered especially with a targeting platform such as single domain antibodies in intravenous or intramuscular, intrathecal etc., these can home in to target distal tissues or even cross the blood brain barrier which other nanovehicles cannot.

NanoMEDIC utilizes an HIV-derived Gag protein to package Cas9 protein and gRNA into EVs. The Cas9 and Gag proteins are fused to a heterodimerizer and conditionally dimerized by the addition of an inducible chemical ligand to recruit Cas9 protein into EVs. sgRNA is packaged into EVs through an HIV-derived RNA packaging signal and is subsequently released by two self-cleaving ribozymes. Utilizing these features, NanoMEDIC can achieve highly efficient packaging of the Cas9 protein and gRNA for genome editing into a variety of target cells and in vivo.

A potential predictive biomarker for acute graft-versus-host disease (aGVHD) is extracellular vesicles (EVs), which are inversions of the phospholipid bilayer of various cells that have been implicated in cellular damage, activation, and intercellular signaling.

As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These vesicles can range in size from 30nm to 1,000nm and are collectively known as Extracellular Vesicles (EVs).

In this review, the history of exosomes and the specific biomarkers present in exosomes that enable accurate monitoring of various diseases are described. In addition, methods for analysis of exosomes and identification of biomarkers are presented with special emphasis being given to isolation and signaling strategies. Lastly, integrated, microfluidic systems developed for exosome-based cancer diagnosis are described and future directions that research in this area will likely take are presented.

Circulating tumour cells (CTCs) in blood associate with overall survival (OS) of cancer patients, but they are detected in extremely low numbers. Large tumour-derived extracellular vesicles (tdEVs) in castration-resistant prostate cancer (CRPC) patients are present at around 20 times higher frequencies than CTCs and have equivalent prognostic power.

Platelet-derived extracellular vesicles (PEVs) are small vesicles released by activated platelets that are gaining growing interest in the field of vascular biology. The mode of platelet activation is a critical determinant of PEVs release, phenotype and function. However, only very limited information is available concerning the impact of the platelet purification procedure on PEVs release.